Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel - 2Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
- 3A definitive Bike Standoff: Decision in favor of Your Number one Ride
- 4‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- 5Manual for Tracking down the Mysterious Cascades in China
- Instructions to Investigate Different Open Record Extra Offers Actually
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- 5 Language Learning Applications
- Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- Staggering Spots to Stargaze All over the Planet
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- How effective is the flu shot this year? New report shows promising results
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Pick Your Favored kind of salad
